In summary, addressing the challenges posed by FH deficiency in gynecologic oncology requires a multifaceted approach encompassing early detection, targeted therapies, clinical trials, and ongoing research aimed at also identifying the potential role of FH deficiency in leiomyoma transformation in leiomyosarcoma. Here, FH is linked to leiomyoma.